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Abstract  
Background: The role of the metabolic syndrome in the etiology of esophageal and gastric 
cancer is unclear.  
Methods: This was a large nationwide cohort study based on data from 11 prospective 
population-based cohorts in Norway with long-term follow-up, the Cohort of Norway (CONOR) 
and the third Nord-Trøndelag Health Study (HUNT3). The metabolic syndrome was assessed by 
objective anthropometric and metabolic biochemical measures and was defined by the presence 
of at least three of the following five factors: increased waist circumference, elevated 
triglycerides, low high-density lipoprotein cholesterol, hypertension, and high glucose. Newly 
diagnosed cases of esophageal adenocarcinoma, esophageal squamous-cell carcinoma and gastric 
adenocarcinoma were identified from the Norwegian Cancer Registry. Hazard ratios (HRs) and 
95% confidence intervals (CIs) were estimated using Cox proportional hazard models with 
adjustment for potential confounders. 
Result: Among 192,903 participants followed up for an average of 10.6 years, 62 developed 
esophageal adenocarcinoma, 64 had esophageal squamous-cell carcinoma and 373 had gastric 
adenocarcinoma. The metabolic syndrome was significantly associated with an increased risk of 
gastric adenocarcinoma (HR=1.44, 95% CI: 1.14-1.82), but not associated with esophageal 
adenocarcinoma (HR=1.32, 95% CI: 0.77-2.26) or esophageal squamous-cell carcinoma 
(HR=1.08, 95% CI: 0.64-1.83). Increased waist circumference was associated with an increased 
HR of esophageal adenocarcinoma (HR=2.48, 95% CI: 1.27-4.85). No significant association 
was found between any single component of the metabolic syndrome and risk of esophageal 
squamous-cell carcinoma. High waist circumference (HR=1.71, 95% CI: 1.05-2.80), 
hypertension (HR=2.41, 95% CI: 1.44-4.03) and non-fasting glucose (HR=1.74, 95% CI: 1.18-
2.56) were also related to an increased risk of gastric adenocarcinoma in women, but not in men. 
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Conclusion: Metabolic syndrome was associated with an increased risk of gastric 
adenocarcinoma in women. Of the individual components of the metabolic syndrome, high waist 
circumference was positively associated with risk of esophageal adenocarcinoma. Positive 
associations were also observed for women between high waist circumference, hypertension, 
high non-fasting glucose and risk of gastric adenocarcinoma. However, further evidence is 
warranted due to the limited number of cases and the inability to effectively identify gastric 
cardia adenocarcinoma. 
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Introduction 
 
Esophageal and gastric cancers are two of the most common cancers worldwide. Globally, 
esophageal cancer ranks eighth in incidence and sixth in cancer-related mortality, while gastric 
cancer ranks fourth and second, respectively.(1) The precise etiology for these tumors still 
remains unclear. Metabolic syndrome, which is defined by the presence of at least 3 out of the 5 
factors abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol (HDL), 
hypertension, and high fasting glucose,(2) is becoming an almost ubiquitous severe health issue 
across the globe. It is estimated that more than 40% of U.S. residents over the age of 60 years 
have metabolic syndrome,(3) with a prevalence of approximately 25% in European and Latin 
populations.(4, 5) Originally, the concern regarding metabolic syndrome was primarily focused 
on its contribution to increased cardiovascular disease and type 2 diabetes mellitus risk. However, 
recent evidence has shown a carcinogenic role of the metabolic syndrome in certain types of 
cancer.(6-11) However to date, epidemiological studies on metabolic syndrome and 
gastroesophageal cancer are sparse. There is, to the best of our knowledge, only one study that 
has addressed the association between the metabolic syndrome and risk of esophageal cancer, and 
one of gastric cancer.(12, 13) Abdominal obesity has been suggested to contribute to the 
increased risk of esophageal and gastric adenocarcinoma,(14, 15) while the role of other variables 
that constitute the metabolic syndrome is uncertain. The aim of the present study was to 
investigate the relation between the metabolic syndrome and the risk of esophageal 
adenocarcinoma, esophageal squamous-cell carcinoma and gastric adenocarcinoma using a large 
population-based cohort study with long-term follow-up in Norway. 
 
 
 
 
6 
 
Methods 
 
Study design and participants 
This study was based on the Cohort of Norway (CONOR) and the third Nord-Trøndelag Health 
Study (HUNT3). The details of both these cohorts have been described previously.(16, 17) In 
brief, CONOR is a collaborative project between the Norwegian Institute of Public Health and 
universities in Oslo, Bergen, Trondheim, and Tromsø, where data from 10 regional health 
surveys have been combined into one national database. The study started   in 1994 and includes 
individuals from 20 to 103 years of age. Among 309,742 invited individuals of ages ≥20 years, 
180,546 (58.3%) participated in CONOR.
16
 The HUNT study is an ongoing large total 
population-based cohort started in the 1980s in Nord-Trøndelag County, Norway. Two waves of 
HUNT surveys are included in the current study: HUNT2 (1995-1997) and HUNT3 (2006-2008). 
Every resident of Nord-Trøndelag County aged 20 years or older (or turning 20 years during the 
year of survey) was invited. The participants in HUNT2 (65,237) are included in CONOR, but in 
the present study the participatns in HUNT3 are also included. In HUNT3, all 93,860 eligible 
residents above 20 years in the county were invited and 50,807 of them participated (54.1%).(17)  
 
In both the CONOR and HUNT3 surveys, the comprehensive data collection came from 
questionnaires, clinical examinations and blood samples, which included waist and hip 
circumference, serum level of HDL, triglycerides, height, weight, blood pressure, and serum level 
of non-fasting glucose. The present study was approved by the Regional Committee for Medical 
and Health Research Ethics, Central (ID 2012/853). 
 
 
 
7 
 
Study sample 
37,059 of the 50,807 HUNT3 participants also participated in HUNT2, which is included in 
CONOR. Therefore, the 13,748 participants who participated only in HUNT3 were added to the 
total CONOR sample to comprise the current study. The final study cohort included 194,294 
participants from CONOR (n=180,546) and HUNT3 (n=13,748) together. After exclusion of 
participants without a participation date (n=53), or any cancer before the study recruitment 
(n=1,261), 192,903 participants remained for the final analysis.  
 
Case ascertainment and follow-up 
All newly diagnosed cases of esophageal adenocarcinoma, esophageal squamous-cell carcinoma 
and gastric adenocarcinoma were retrieved from linkage to the Cancer Registry of Norway, 
which was established in 1951 and is considered a complete and reliable registry.(18)  
Esophageal cancer was identified by the seventh revision of International Classification of 
Diseases (ICD-7) code ‘150’ and further categorized into adenocarcinoma and squamous-cell 
carcinoma by morphological codes in International Classification of Diseases for Oncology, 
Third Edition (ICD-O-3) (Supplementary Table 1 ).(19) Gastric cancer was defined with ICD-7 
code ‘151’. Due to the fact that gastric cardia cancer was included in the same code (ICD-7 code 
‘1512’) as cancer in the fundus and upper stomach, it was not possible to separate gastric cardia 
and non-cardia cancer. Gastric adenocarcinoma histology was identified among all gastric 
cancers followed by the relevant morphological code in ICD-O-3. Determination of date of death 
and emigration was accomplished from Statistics Norway. All participants were followed up 
from the date of entry into the cohort until the date of diagnosis of esophageal adenocarcinoma, 
esophageal squamous-cell carcinoma, or gastric adenocarcinoma, any other cancer, death, 
emigration, or the end of the study period (31st, December, 2010), whichever came first. To 
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avoid detection bias, we also conducted a sensitivity analysis excluding all persons-years during 
the first two years of follow-up. Since the results of the main analysis and the sensitivity analysis 
were similar, we present the results of the sensitivity results in supplementary Table 2.  
 
Measurement of individual components of metabolic syndrome 
Blood samples were collected and the serum was separated by centrifuging at the screening site. 
The Department of Clinical Chemistry, Ullevål or University Hospital, Oslo, performed all 
laboratory assessments for CONOR, except for HUNT2.(17) Study samples from HUNT2 and 
HUNT3 were analyzed at the Department of Clinical Chemistry, Levanger Hospital. 
Comparisons between the blood-samples analyzed in the different laboratories revealed small 
differences.(17)  
 
Systolic and diastolic blood pressure was measured using an automatic device (Dinamap, 
Criticon, USA). Height and weight were measured with the participants wearing light clothes 
without shoes. Waist and hip circumference were measured with a band to the nearest full 
centimeter, with the participants standing and with the arms hanging relaxed. The waist 
circumference was measured at the height of the umbilicus, and the hip circumference was 
measured at the thickest part of the hip.  
 
Statistical analysis 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using Cox proportional 
hazard models, with follow-up of person-days as the underlying time metric.(20) The 
proportional hazards assumption was tested for potential confounders (presented below), and all 
variables conformed to the assumption of proportionality. The exposure to metabolic syndrome 
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related factors was categorized into groups based on clinical cut-off points defined  in 2009 for 
the metabolic syndrome(2): waist circumference (women <80 cm, men <94 cm, or women ≥80 
cm, men ≥94 cm), HDL (women ≥1.3 mmol/L, men ≥1.0 mmol/L, or women <1.3 mmol/L, men 
<1.0 mmol/L), triglycerides (<1.7 mmol/L or ≥1.7 mmol/L), and fasting glucose (<5.6 mmol/L or 
≥5.6 mmol/L). Hypertension was defined as systolic blood pressure ≥130 mm Hg, or diastolic 
blood pressure ≥85 mm Hg. The metabolic syndrome was defined based on previous research by 
the presence of three or more of the following five factors: increased waist circumference, 
elevated triglycerides, low HDL, hypertension, and high fasting glucose.(2)  In the current study, 
we used non-fasting glucose as an index for fasting glucose, adjusting for time (in hours) since 
last meal. As previous studies have indicated a women-specific effect of metabolic syndrome on 
the risk of gastric adenocarcinoma, we also categorized the analysis by gender. 
 
Possible confounding or effect modification by the following known risk factors for esophageal 
or gastric cancer were considered: age (categorized into two groups: <60 or ≥60 years), sex 
(female or male), education (primary/secondary school, high school, or university), body mass 
index (BMI) (<25, 25-29.9, or ≥30 kg/m2), tobacco smoking status (yes or no), alcohol drinking 
(>4, 4, 2-3, 1 times per week, or none), and family history of cancer (yes or no). The basic model 
included adjustment for age and sex only, while the full model adjusted for all variables listed 
above. In the analysis of non-fasting glucose, time since last meal (<3, 3-5, or ≥5 hours) was 
added into the full model. Since exposure to non-fasting glucose, waist circumference, education 
and alcohol consumption had more than 10% missing values, we developed various strategies to 
reduce the potential bias that could be induced by missing values. For the continuous variables, 
non-fasting glucose and waist circumference, multiple imputation was used to impute the missing 
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values.(21) With this approach, a model is posited for the association between missing values and 
recorded values, using records in which the non-fasting glucose and waist circumference data are 
available. All potential confounders mentioned above, as well as cancer diagnosis status and 
metabolic syndrome components were accounted for in this model. The model is used to generate 
several replicate ‘completed’ data sets (n=5), where the imputed values were produced to replace 
those missing values. By combining results from these completed data sets, valid statistical 
inferences of parameters of interest are then generated using multiple imputation rules.(21) For 
the categorical variables education and alcohol consumption, we kept all the missing values as a 
separate category. The SAS Statistical Package (version 9.2, SAS institute, Gary, NC) was used 
for all analyses. 
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Results 
 
Study participants 
During follow-up of 192,903 participants for an average of 10.6 years (2,050,335 person-years at 
risk), 62 esophageal adenocarcinoma, 64 esophageal squamous-cell carcinoma, and 373 gastric 
adenocarcinoma were identified. Baseline characteristics of the cohort members are shown in 
Table 1. The mean age at entrance into the cohort was 49.5 years, while the mean age for cancer 
cases was 65.0 years. Cases of esophageal adenocarcinoma and gastric adenocarcinoma had 
higher frequencies of metabolic syndrome and higher waist circumference than the non-cases 
group (all p value<0.05, data not shown). Hypertension was overrepresented in all cancer case 
groups, compared to the control cohort (p<0.05, data not shown). Distribution of high level of 
non-fasting glucose was highest among cases of esophageal squamous-cell carcinoma and gastric 
adenocarcinoma compared to the control cohort (all p values<0.05, data not shown).  
 
Metabolic syndrome and risk of esophageal adenocarcinoma 
The metabolic syndrome as a composite index was not statistically significantly associated with 
an increased risk of esophageal adenocarcinoma (HR 1.32, 95% CI: 0.77-2.26) (Table 2). 
Compared to a lower waist circumference, a higher waist circumference was followed by an 
increased HR of this cancer (HR 2.48, 95% CI: 1.27- 4.85). None of the other four components of 
the metabolic syndrome (HDL, triglycerides, hypertension, and glucose) were significantly 
associated with any increased risk of esophageal adenocarcinoma (Table 2). 
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Metabolic syndrome and risk of esophageal squamous-cell carcinoma 
The metabolic syndrome was not associated with increased risk of esophageal squamous-cell 
carcinoma (HR 1.08, 95% CI: 0.64-1.83). High glucose levels were borderline associated with an 
increased risk of this cancer (HR 1.70, 95% CI: 1.00-2.90). There were no clear associations with 
any of the other constituents of the metabolic syndrome (Table 2). 
 
Metabolic syndrome and risk of gastric adenocarcinoma 
In the total population, presence of the metabolic syndrome was associated with a 44% increased 
risk of gastric adenocarcinoma (HR 1.44, 95% CI 1.14-1.82). When the analysis was stratified by 
sex, 64% (HR 1.64, 95% CI 1.07-2.49), and 36% (HR 1.36, 95% CI 1.01-1.84) increased risks 
were observed in women and men, respectively. Among women, increased HRs of this cancer 
were also found for participants with higher waist circumference (HR 1.71, 95% CI 1.05-2.80), 
hypertension (HR 2.41, 95% CI 1.44-4.03) and higher glucose levels (HR 1.74, 95% CI 1.18-2.56) 
(Table 3). No single component of the metabolic syndrome was associated with risk of gastric 
adenocarcinoma in men. 
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Discussion 
 
An increased risk of gastric adenocarcinoma was identified with the presence of the metabolic 
syndrome, while no such statistically significant associations were found between the metabolic 
syndrome and risk of esophageal adenocarcinoma or squamous-cell carcinoma. Among the 
individual components of the metabolic syndrome, high waist circumference was associated with 
an increased risk of esophageal adenocarcinoma, and high waist circumference, hypertension, 
and high glucose with an increased risk of gastric adenocarcinoma in women, but not men.  
 
Strengths of the present study include the prospective and population-based design, the detailed 
and objectively assessed exposure information of components of the metabolic syndrome, the 
reliable identification of cancer cases through the national cancer registry, the virtually complete 
follow-up of all cohort members, and the availability of several confounders. However, some 
potential confounders, i.e. gastroesophageal reflux and Helicobacter pylori infection are not 
available. Moreover, the variables education and alcohol drinking had more than 10% of missing 
values, leaving a risk for residual confounding. Although this study included over 2 million 
person-years at risk, the limited number of cancer cases is a weakness, reducing the power to find 
weaker associations. Another limitation of the exposure assessment was that glucose levels were 
not fully fasting values. However, we added the time (in hours) since last meal in the adjustment 
in order to attenuate the potential bias. Since the misclassification of the exposure in a 
prospective study design would be similarly distributed among cases and controls, the influence 
on the results would tend to be non-differential. Finally, since the cardia cancer is different from 
the non-cardia cancer in clinical and pathological features, as well as in prognosis, we cannot rule 
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out potential selection bias due to the fact that cardia cancer could not be distinguished from 
overall gastric cancer. 
 
Although we did not observe any statistically significant association between the metabolic 
syndrome and esophageal adenocarcinoma, the component high waist circumferences was a risk 
factor. The latter observation gains support from other studies.(14, 22, 23) After 11.3 years 
follow-up in 41,295 individuals, an Australian study reported an HR of 2.9 (95% CI 1.2-6.9) 
when comparing the highest and the lowest tertile of waist circumference.(22) In the European 
Prospective Investigation into Cancer and Nutrition study, 346,544 adults were followed for 8.9 
years and revealed a relative risk of 3.07 (95% CI 1.35-6.98) of  esophageal or gastroesophageal 
junctional adenocarcinoma comparing participants in the highest and lowest quintile of waist 
circumference.(23) There are several potential mechanisms behind this association, including an 
increased intra-abdominal pressure caused by abdominal obesity, which increases the risk of 
gastroesophageal reflux, a strong risk factor for esophageal adenocarcinoma.(24-26) Abdominal 
obesity is also associated with increased hormone levels, such as insulin-like growth factor and 
adiponectin, which are known to influence cell division, cell death, and healing.(27, 28) 
 
It should be noticed that, the CONOR has been included in a pooling study by Lindkvist et al. to 
investigate the association between metabolic syndrome and risk of esophageal cancer.(12)  
However, two key components of the metabolic syndrome, waist circumference and HDL, were 
not applied in that study. This may have led to misclassification of the metabolic syndrome and 
limited the scientific value of the study. In line with the previous study by Lindkvist et. al,(12) 
we did not observe a significant association between overall metabolic syndrome and risk of 
esophageal squamous-cell carcinoma. Waist circumference, HDL, triglycerides, hypertension and 
15 
 
non-fasting glucose were also not associated with esophageal squamous-cell carcinoma in the 
current study. In contrast, Lindkvist and his colleagues found a strong and dose dependent 
association between mid-blood pressure ((systolic BP+diastolic BP)/2) and risk of esophageal 
squamous-cell carcinoma, but alcohol consumption was considered a potential confounding 
factor that they were not able to adjust for.(12) An increased risk of esophageal cancer in general 
related to hypertension diagnosed below the age of 60 years was recently reported,(29) but to 
date, no other studies have been able to explore the association between hypertension and 
esophageal squamous-cell carcinoma. 
 
The finding of an association between the metabolic syndrome and the risk of gastric 
adenocarcinoma is interesting.(13) In the only previous study addressing this association, z-score 
standardization was used to create a composite metabolic syndrome score, which was found to be 
borderline associated with risk of gastric adenocarcinoma in women, but not men. In contrast, we 
found that metabolic syndrome as an overall condition was associated with gastric 
adenocarcinoma in both women and men. The chronic inflammation induced by the metabolic 
syndrome and its mediators might be involved in tumor development.(30) 
  
Participants with high waist circumference were found to have a 50% higher risk of gastric 
adenocarcinoma. There is strong evidence showing the positive association between esophageal 
and gastric cardia adenocarcinoma and abdominal obesity, but it remains unclear whether there is 
an association with gastric non-cardia adenocarcinoma. In a large prospective study in the U.S. 
including 191 cardia and 125 non-cardia cancers, a positive association between cardia gastric 
cancer and waist circumference (HR 2.22, 95% CI 1.4-3.5) was observed. No association was 
observed for abdominal obesity and non-cardia gastric cancer.(31) However, in the current study 
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we could not conclude whether the observed association was relevant only for cardia cancer or 
both cardia and non-cardia cancer. Interestingly, this association seems to be women-specific, 
and not seen in men. Possible mechanisms linking obesity and gastric cancer may include obesity 
associated gastro-esophageal reflux, abnormal gastric motility, insulin resistance, altered levels of 
metabolic endogenous hormones, and an abnormally increased blood level of insulin-like growth 
factor (IGF).(32) Recent evidence has revealed an increased prevalence of Helicobacter pylori 
infection in the obese patients, providing another indication for the increased incidence of gastric 
cancer in obese population. Further research with separate cardia and non-cardia cancer cases is 
needed to clarify the potential association with increased waist circumference.  
 
Our finding of a moderate association between hypertension and risk of gastric adenocarcinoma 
is partly supported by the previous study, which suggests that patients with self-reported 
hypertension history may be at a 2-fold increased risk of adenocarcinoma of esophagus and 
gastric cardia.(33) Hypertension is the most prevalent cardiovascular condition in the United 
States and affects over 60 million people. Men have a higher prevalence of hypertension than 
women (38% versus 29%). The prevalence of elevated blood pressure in American youth was 9.3% 
among female subjects and 18.5% among male subjects.(34) The mechanism is unclear, but it is 
plausible that hypertension and malignancy might share some common biochemical pathways. 
For example, increased production of inositol triphosphate and increased levels of cytosolic 
calcium are likely to be involved in the pathogenesis of hypertension and in the early events of 
cell proliferation that are activated by endogenous mitogens and oncogenes.(35)  
 
Among other individual components of the metabolic syndrome in the previous study,(13) fasting 
glucose was the single factor that was significantly associated with the risk of gastric 
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adenocarcinoma in women. This finding is supported by our results, with increased risk estimates 
for high glucose levels (non-fasting) and risk of gastric adenocarcinoma. Glucose has also been 
indicated as an independent risk factor for gastric cancer in other studies.(36) The role that high 
serum glucose level plays in the development of gastric adenocarcinoma needs to be assessed 
further in a larger epidemiological study. 
 
In conclusion, this population-based cohort study with objective assessment of all components of 
the metabolic syndrome revealed an association with gastric adenocarcinoma in women, but not 
so clearly for esophageal adenocarcinoma or squamous cell carcinoma. Of the individual 
components of the metabolic syndrome, high waist circumference was associated with an 
increased risk of esophageal adenocarcinoma, while women with high waist circumference, 
hypertension, and high glucose were under higher risk of gastric adenocarcinoma. There is, 
however, a need for further large-scale and prospective studies to demonstrate any role of the 
metabolic syndrome in the etiology of esophageal and gastric cancer. 
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Table 1.Baseline characteristics. 
 
 
Esophageal 
adenocarcinoma 
Esophageal 
squamous-cell 
carcinoma 
Gastric 
adenocarcinoma 
Total cohort 
Subject, n 62 64 373 192,903 
Average follow up years (±std†) 6.9 (±3.8) 5.1 (±3.6) 5.9 (±3.9) 10.6 (±4.0) 
Person years 428 325 1,612 2,050,335 
Age at participation (±std†) 64.1 (±10.2) 65.0 (±11.4) 65.1 (±11.8) 49.5 (±15.7) 
Sex, n (%) 
    1 Women 7 (11.3%) 27 (42.2%) 153 (41.0%) 99,845 (51.8%) 
2 Men 55 (88.7%) 37 (57.8%) 220 (59.0%) 93,058 (48.2%) 
BMI 
    1 (<25 kg/m
2
) 8 (12.9%) 32 (50.0%) 136 (36.5%) 83,542 (43.3%) 
2 (25-30 kg/m
2
) 46 (74.2%) 22 (34.4%) 165 (44.2%) 78,488 (40.7%) 
3 (≥30 kg/m2) 8 (12.9%) 10 (15.6%) 72 (19.3%) 29,667 (15.4%) 
Missing 0 0 0 1,206 (0.6%) 
Smoking status, n (%)     
  1 No 43 (69.4%) 25 (39.1%) 250 (67.0%) 129,363 (67.1%) 
  2 Yes 19 (30.6%) 38 (59.4%) 120 (32.2%) 55,186 (28.6%) 
Missing 0 1 (1.5%) 3 (0.8%) 8,354 (4.3%) 
Education 
    1 (primary/secondary school) 13 (21.0%) 24 (37.5%) 157 (42.1%) 43,639 (22.6%) 
2 (high school) 20 (32.2%) 11 (17.2%) 69 (18.5%) 57,210 (30.6%) 
3 (university) 4 (6.5%) 5 (7.8%) 23 (6.2%) 21,137 (11.0%) 
Missing 25 (40.3%) 24 (37.5%) 124 (33.2%) 70,917 (36.8%) 
Family cancer history     
1 No 47 (75.8%) 46 (71.9%) 253 (67.8%) 144,534 (74.9%) 
2 Yes 15 (24.2%) 18 (28.1%) 120  (32.2%) 48,369 (25.1%) 
Alcohol drinking (times/week)     
1 (>4 times) 18 (29.0%) 14 (21.9%) 36 (9.7%) 28,669 (14.9%) 
2 (4 times) 10 (16.1%) 8 (12.5%) 63 (16.9%) 34,184 (17.7%) 
3 (2-3 times) 11 (17.7%) 11 (17.2%) 60 (16.1%) 41,086 (21.3%) 
4 (1 time) 5 (8.1%) 2 (3.1%) 23 (6.0%) 17,599 (9.1%) 
5 (none) 12 (19.4%) 17 (26.5%) 128 (34.3%) 52,299 (27.1%) 
Missing 6 (9.7%) 12 (18.8%) 54 (16.0%) 19,066 (9.9%) 
Metabolic syndrom‡     
1 No 25 (40.3%) 33 (51.5%) 161 (43.2%) 117,376 (60.9%) 
2 Yes 37 (59.7%) 31 (48.5%) 212 (56.8%) 75,686 (39.1%) 
Waist circumference      
1 (women<80, men< 94 cm)  12 (19.4%) 24 (37.5%) 114 (30.6%) 85,266 (44.2%) 
2 (women ≥80, men ≥94 cm) 50 (80.6%) 40 (62.5%) 259 (69.4%) 107,637 (55.8%) 
High-density lipoprotein cholesterol (HDL)    
1 (women ≥1.3, men ≥1.0 mmol/L) 52 (83.9%) 52 (81.3%) 279 (74.8%) 145,286 (75.3%) 
2 (women<1.3, men<1.0 mmol/L) 10 (16.1%) 11 (17.2%) 90 (24.1%) 46,671 (24.2%) 
Triglycerides  
    1 (<1.7 mmol/L) 29 (46.8%) 43 (67.2%) 211 (56.7%) 121,012 (62.7%) 
2 (≥1.7 mmol/L) 33 (53.2%) 21 (32.8%) 160 (42.9%) 71,216 (36.9%) 
 
0 0 2 (0.4%) 675 (0.4%) 
Hypertension§ 
    1 No 17 (27.4%) 13 (20.3%) 78 (20.9%) 86,243 (44.7%) 
2 Yes 45 (72.6%) 51 (79.7%) 295 (79.1%) 106,660 (55.3%) 
Non-fasting glucose     
1 (<5.6 mmol/L) 31 (50.0%) 27 (42.2%) 173 (46.4%) 117,381 (60.9%) 
2 (≥5.6 mmol/L) 31 (50.0%) 37 (57.8%) 200 (53.6%) 75,522 (39.1%) 
 
† Standard deviation 
‡ Metabolic syndrome was defined by the presence of ≥3 of following 5 factors: increased waist circumference (men≥94 cm, 
women≥80 cm), elevated triglycerides (≥1.7 mmol/L), low HDL (men<1.0 mmol/L, women<1.3 mmol/L), hypertension (systolic 
blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg), and high non-fasting glucose (≥5.6 mmol/L). 
§ Hypertension was defined with systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg.  
 
Table 2. Hazard ratio (HR) with 95% confidence interval for incident esophageal adenocarcinoma and 
esophageal squamous-cell carcinoma related to metabolic syndrome. 
 
Esophageal adenocarcinoma Esophageal squamous-cell carcinoma 
Exposure No. HR
†
 HR
‡
 No. HR
†
 HR
§
 
       Metabolic syndrome# 
     No 25 1.0 1.0 33 1.0 1.0 
Yes 37 1.54 (0.93-2.57) 1.32 (0.77-2.26) 31 0.98 (0.60-1.61) 1.08 (0.64-1.83) 
       Waist circumference 
      Women<80 cm, men<94 cm 12 1.0 1.0 24 1.0 1.0 
Women≥80 cm, men≥94 cm 50 3.05 (1.62-5.75) 2.48 (1.27-4.85) 40 1.05 (0.63-1.75) 1.19 (0.71-2.00) 
       HDL 
      Women≥1.3 mmol/L, 
men≥1.0 mmol/L 52 1.0 1.0 52 1.0 1.0 
Women<1.3 mmol/L, 
men<1.0 mmol/L 10 0.87 (0.44-1.72) 0.76 (0.38-1.52) 11 0.77 (0.40-1.49) 0.70 (0.35-1.40) 
       Triglycerides 
      <1.7 mmol/L 29 1.0 1.0 43 1.0 1.0 
≥1.7 mmol/L 33 1.35 (0.82-2.22) 1.15 (0.69-1.91) 21 0.65 (0.38-1.10) 0.68 (0.40-1.15) 
       Hypertension¤ 
      No 17 1.0 1.0 13 1.0 1.0 
Yes 45 0.90 (0.51-1.60) 0.82 (0.46-1.46) 51 1.52 (0.80-2.88) 1.62 (0.85-3.08) 
       Non-fasting glucose^ 
      <5.6 mmol/L 31 1.0 1.0 27 1.0 1.0 
≥5.6 mmol/L 31 1.09 (0.66-1.80) 1.06 (0.63-1.78) 37 1.63 (0.99-2.69) 1.70 (1.00-2.90) 
† Adjusted for age (<60, ≥60 years), sex (women, men). 
‡ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30, ≥ 30 kg/m2), education 
(primary/secondary school, high school, university), smoking status (no, yes); family cancer history (no, yes). 
§ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30, ≥ 30 kg/m2), education 
(primary/secondary school, high school, university), smoking status (no, yes), alcohol intake (>4, 4, 2-3, 1 times 
per week, and none), family cancer history (no, yes). 
# Metabolic syndrome was defined by the presence of ≥3 of following 5 factors: increased waist circumference 
(men≥94 cm, women≥80 cm), elevated triglycerides (≥1.7 mmol/L), low HDL (men<1.0 mmol/L, women<1.3 
mmol/L), hypertension (systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg), and high 
non-fasting glucose (≥5.6 mmol/L). 
^ Additionally adjusted for time since last meal (<3, 3-5, ≥5 hours). 
 
 
 
 
Table 3. Hazard ratio (HR) with 95% confidence interval for incident gastric adenocarcinoma related to metabolic syndrome. 
 
 
Total Women Men 
Exposure No. HR
†
 HR
‡
 No. HR
†
 HR
§
 No. HR
†
 HR
§
 
          Metabolic syndrome# 
       No 161 1.0 1.0 66 1.0 1.0 95 1.0 1.0 
Yes 212 1.38 (1.12-1.70) 1.44 (1.14-1.82) 87 1.40 (1.00-1.95) 1.64 (1.07-2.49) 125 1.36 (1.04-1.78) 1.36 (1.01-1.84) 
          Waist circumference 
        Men<94 cm, women<80 cm 114 1.0 1.0 40 1.0 1.0 74 1.0 1.0 
Men≥94 cm, women≥80 cm 259 1.43 (1.14-1.79) 1.47 (1.14-1.90) 113 1.33 (0.92-1.92) 1.71 (1.05-2.80) 146 1.49 (1.12-1.97) 1.38 (1.00-1.91) 
          HDL 
         Men≥1.0 mmol/L, 
women≥1.3 mmol/L 279 1.0 1.0 111 1.0 1.0 168 1.0 1.0 
Men<1.0 mmol/L, 
women<1.3 mmol/L 90 1.20 (0.94-1.54) 1.18 (0.92-1.50) 42 1.00 (0.70-1.42) 1.02 (0.67-1.56) 48 1.41 (1.02-1.95) 1.34 (0.97-1.87) 
          Triglycerides 
        <1.7 mmol/L 211 1.0 1.0 95 1.0 1.0 116 1.0 1.0 
≥1.7 mmol/L 160 1.02 (0.83-1.26) 0.99 (0.80-1.23) 58 1.04 (0.74-1.46) 1.00 (0.67-1.49) 102 1.00 (0.77-1.31) 0.95 (0.72-1.25) 
          Hypertension¤ 
        No 78 1.0 1.0 32 1.0 1.0 46 1.0 1.0 
Yes 295 1.54 (1.19-2.01) 1.52 (1.16-1.98) 121 2.09 (1.35-3.22) 2.41 (1.44-4.03) 174 1.27 (0.91-1.77) 1.24 (0.88-1.73) 
          Non-fasting glucose^ 
        <5.6 mmol/L 173 1.0 1.0 69 1.0 1.0 104 1.0 1.0 
≥5.6 mmol/L 200 1.33 (1.08-1.63) 1.36 (1.10-1.69) 84 1.56 (1.13-2.15) 1.74 (1.18-2.56) 116 1.19 (0.91-1.55) 1.22 (0.92-1.62) 
† Adjusted for age (<60, ≥60 years). 
‡ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30,≥ 30 kg/m2 ), education (primary/secondary school, high school, university), smoking status (no, 
yes); family cancer history (no, yes). 
§ Adjusted for age (<60, ≥60 years), BMI (<25, 25-30,≥ 30 kg/m2 ), education (primary/secondary school, high school, university), smoking status (no, yes); family cancer 
history (no, yes). 
# Metabolic syndrome was defined by the presence of ≥3 of following 5 factors: increased waist circumference (men≥94 cm, women≥80 cm), elevated triglycerides (≥1.7 
mmol/L), low HDL (men<1.0 mmol/L, women<1.3 mmol/L), hypertension (systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg), and high non-
fasting glucose (≥5.6 mmol/L). 
^ Additionally adjusted for time since last meal (<3, 3-5, ≥5 hours). 
Supplemental table 1. List of morphological codes in ICD-O-3 used to differentiate the histological 
types of esophageal and gastric cancer 
Adenocarcinoma 
8140/3 Adenocarcinoma, NOS 
8141/3 Scirrhous adenocarcinoma 
8144/3 Adenocarcinoma, intestinal type (C16._)   
8145/3 cardinoma, diffuse type (adenocarcinoma, diffuse type) (C16._)  
8147/3 basal cell adenocarcinoma 
8150/3 Islet cell carcinoma (C25._) 
8154/3 Mixed islet cell and exocrine adenocarcinoma (C25._)  
8190/3 Trabecular adenocarcinoma 
8210/3 adenocarcinoma in adenomatous polyp 
8211/3 tubular adenocarcinoma 
8214/3 parietal cell carcinoma (parietal cell adenocarcinoma) (C16._)   
8215/3 Adenocarcinoma of anal glands (C21.1)  
8220/3 Adenomatous polyposis coli (C18._) 
8221/3 adenocarcinoma in multiple adenomatous polys 
8250/3 Bronchiolo-alveolar adenocarcinoma, NOS (C34._) 
8251/3 Alveolar adenocarcinoma (C34._)   
8255/3 adenocarcinoma with mixed subtypes 
8260/3 Papillary adenocarcinoma, NOS 
8261/3 adenocarcinoma in villous adenoma 
8262/3 villous adenocarcinoma 
8263/3 adenocarcinoma in tubolovillous adenoma 
8270/3 Chromophobe carcinoma (C75.1) (Chromophobe adenocarcinoma (C75.1) 
8290/3 Oxyphilic adenocarcinoma 
8300/3 Basophil carcinoma (C75.1) (Basophil adenocarcinoma (C75.1); Mucoid cell 
adenocarcinoma (C75.1)) 
8310/3 clear cell adenocarcinoma 
8320/3 Granular cell carcinoma (Granular cell adenocarcinoma) 
8322/3 Water-clear cell adenocarcinoma (C75.0) 
8323/3 mix cell adenocarcinoma 
8330/3 Follicular adenocarcinoma, NOS (C73.9) 
8331/3 Follicular adenocarcinoma, well differentiated (C73.9)  
8332/3 Follicular adenocarcinoma, trabecular (C73.9) 
8333/3 Fetal adenocarcinoma 
8380/3 Endometrioid adenocarcinoma, NOS 
8382/3 Endometrioid adenocarcinoma, secretory variant 
8383/3 Endometrioid adenocarcinoma, ciliated cell variant 
8384/3 Adenocarcinoma, endocervical type 
8400/3 Sweat gland adenocarcinoma (C44._)  
8401/3 Apocrine adenocarcinoma 
8408/3 Eccrine papillary adenocarcinoma (C44._) SKIN 
8410/3 Sebaceous adenocarcinoma (C44._) SKIN 
8413/3 Eccrine adenocarcinoma (C44._) 
8420/3 Ceruminous adenocarcinoma (C44.2) 
8480/3 mucinous adenocarcinoma 
8481/3 mucin-producing adenocarcinoma 
8482/3 Mucinous adenocarcinoma, endocervical type 
8490/3  signet ring cell carcinoma 
8503/2 Noninfiltrating intraductal papillary adenocarcinoma (C50._)   
8503/3 Intraductal papillary adenocarcinoma (C50._)   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8504/3 Intracystic carcinoma, NOS (Intracystic pallilary adenocarcinoma) 
8510/3 Medullary carcinoma, NOS (Medullary adenocarcinoma) 
8525/3 Polymorphous low grade adenocarcinoma 
8530/3 Inflammatory carcinoma (C50._) (Inflammatory adenocarcinoma (C50._)) 
8571/3 adenocarcinoma with cartilaginous and osseous metaplasisa 
8572/3 adenocarcinoma with spindle cell metaplasia 
8573/3 adenocarcinoma with apocrine metaplasia 
8574/3 Adenocarcinoma with neuroendocrine differentiation 
8576/3 Hepatoid adenocarcinoma 
  
Esophageal squamous-cell  carcinoma 
8052/3 Papillary squamous cell carcinoma 
8070/3 squamous-cell carcinoma, NOS 
8071/3 squamous-cell carcinoma, keratinizing 
8072/3 squamous cell carcinoma, large cell, nonkeratinizing, NOS 
8073/3 Squamous cell carcinoma, small cell, nonkeratinizing 
8074/3 squamous cell carcinoma, spindle cell 
8075/3 Squamous cell carcinoma, microinvasive 
8076/3 Squamous cell carcinoma, microinvasive 
8078/3 squamous cell carcinoma with horn formation 
Supplemental table 2. Hazard ratio (HR) with 95% confidence interval for incident esophageal 
adenocarcinoma and esophageal squamous-cell carcinoma related to metabolic syndrome with first 
two years follow-up excluded. 
 
Esophageal adenocarcinoma Esophageal squamous-cell carcinoma 
Exposure No. HR
†
 HR
‡
 No. HR
†
 HR
§
 
       Metabolic syndrome# 
     No 21 1.0 1.0 24 1.0 1.0 
Yes 31 1.53 (0.88-2.68) 1.07 (0.52-2.21) 19 0.83 (0.45-1.53) 2.52 (0.94-6.74) 
       Waist circumference 
      Women<80 cm, men<94 cm 10 1.0 1.0 15 1.0 1.0 
Women≥80 cm, men≥94 cm 42 3.08 (1.54-6.17) 1.79 (0.76-4.18) 28 1.23 (0.65-2.32) 2.03 (0.79-5.20) 
       HDL 
      Women≥1.3 mmol/L, 
men≥1.0 mmol/L 45 1.0 1.0 36 1.0 1.0 
Women<1.3 mmol/L, 
men<1.0 mmol/L 7 0.70 (0.32-1.57) 0.46 (0.16-1.33) 6 0.63 (0.26-1.51) 0.65 (0.19-2.24) 
       Triglycerides 
      <1.7 mmol/L 24 1.0 1.0 27 1.0 1.0 
≥1.7 mmol/L 28 1.38 (0.80-2.38) 0.86 (0.43-1.71) 16 0.78 (0.42-1.45) 1.31 (0.57-3.00) 
       Hypertension¤ 
      No 15 1.0 1.0 11 1.0 1.0 
Yes 37 0.84 (0.45-1.57) 0.66 (0.31-1.44) 32 1.11 (0.54-2.29) 3.39 (0.96-11.95) 
       Non-fasting glucose^ 
      <5.6 mmol/L 27 1.0 1.0 17 1.0 1.0 
≥5.6 mmol/L 25 1.00 (0.58-1.73) 0.86 (0.43-1.72) 26 1.82 (0.98-3.36) 3.00 (1.07-8.46) 
† Adjusted for age (<60, ≥60 years), sex (women, men). 
‡ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30, ≥ 30 kg/m2), education 
(primary/secondary school, high school, university), smoking status (no, yes); family cancer history (no, yes). 
§ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30, ≥ 30 kg/m2), education 
(primary/secondary school, high school, university), smoking status (no, yes), alcohol intake (>4, 4, 2-3, 1 times 
per week, and none), family cancer history (no, yes).  
# Metabolic syndrome was defined by the presence of ≥3 of following 5 factors: increased waist circumference 
(men≥94 cm, women≥80 cm), elevated triglycerides (≥1.7 mmol/L), low HDL (men<1.0 mmol/L, women<1.3 
mmol/L), hypertension (systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg), and high 
non-fasting glucose (≥5.6 mmol/L). 
^ Additionally adjusted for time since last meal (<3, 3-5, ≥5 hours). 
 
 
 
 
Supplemental table 3. Hazard ratio (HR) with 95% confidence interval for incident gastric adenocarcinoma related to metabolic syndrome with first two year 
follow up excluded. 
 
 
Total Women Men 
Exposure No. HR
†
 HR
‡
 No. HR
†
 HR
§
 No. HR
†
 HR
§
 
          Metabolic syndrome# 
       No 127 1.0 1.0 53 1.0 1.0 74 1.0 1.0 
Yes 156 1.23 (0.94-1.62) 1.73 (1.17-2.56) 60 1.17 (0.80-1.73) 1.41 (0.86-2.32) 96 1.35 (0.99-1.83) 1.28 (0.91-1.80) 
          Waist circumference 
        Men<94 cm, women<80 cm 86 1.0 1.0 30 1.0 1.0 56 1.0 1.0 
Men≥94 cm, women≥80 cm 197 1.40 (1.04-1.88) 2.14 (1.36-3.36) 83 1.29 (0.85-1.98) 1.86 (1.03-3.38) 114 1.55 (1.19-2.13) 1.31 (0.91-1.90) 
          HDL 
         Men≥1.0 mmol/L, 
women≥1.3 mmol/L 217 1.0 1.0 89 1.0 1.0 128 1.0 1.0 
Men<1.0 mmol/L, 
women<1.3 mmol/L 62 1.08 (0.78-1.50) 1.06 (0.70-1.60) 24 0.72 (0.46-1.27) 0.68 (0.39-1.63) 38 1.46 (1.01-2.10) 1.36 (0.93-1.97) 
          Triglycerides 
        <1.7 mmol/L 170 1.0 1.0 80 1.0 1.0 90 1.0 1.0 
≥1.7 mmol/L 111 0.86 (0.65-1.14) 0.96 (0.67-1.37) 33 0.70 (0.46-1.06) 0.61 (0.37-1.00) 78 0.98 (0.73-1.33) 0.90 (0.66-1.24) 
          Hypertension¤ 
        No 57 1.0 1.0 23 1.0 1.0 34 1.0 1.0 
Yes 226 1.74 (1.21-2.50) 1.65 (1.04-2.64) 90 2.19 (1.32-3.64) 2.77 (1.49-5.15) 136 1.39 (0.95-2.04) 1.36 (0.92-2.02) 
          Non-fasting glucose^ 
        <5.6 mmol/L 131 1.0 1.0 50 1.0 1.0 81 1.0 1.0 
≥5.6 mmol/L 152 1.43 (1.09-1.88) 1.96 (1.35-2.84) 63 1.58 (1.08-2.30) 1.85 (1.17-2.92) 89 1.16 (0.86-1.58) 1.21 (0.88-1.66) 
† Adjusted for age (<60, ≥60 years). 
‡ Adjusted for age (<60, ≥60 years), sex (women, men), BMI (<25, 25-30,≥ 30 kg/m2 ), education (primary/secondary school, high school, university), smoking status (no, 
yes); family cancer history (no, yes). 
§ Adjusted to age (<60, ≥60 years), BMI (<25, 25-30,≥ 30 kg/m2 ), education (primary/secondary school, high school, university), smoking status (no, yes); family cancer 
history (no, yes). 
# Metabolic syndrome was defined by the presence of ≥3 of following 5 factors: increased waist circumference (men≥94 cm, women≥80 cm), elevated triglycerides (≥1.7 
mmol/L), low HDL (men<1.0 mmol/L, women<1.3 mmol/L), hypertension (systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg), and high non-
fasting glucose (≥5.6 mmol/L). 
^ Additionally adjusted for time since last meal (<3, 3-5, ≥5 hours). 
